ucsf logo

Michael Ohliger, MD, PhD

Diagnostic Radiology
Portrait of Michael Ohliger
Portrait of Michael Ohliger
ucsf logo

Michael Ohliger, MD, PhD

Diagnostic Radiology

On this page

About me

Dr. Michael Ohliger is a radiologist who specializes in abdominal imaging to screen for, diagnose and treat cancer and other conditions affecting the liver, kidneys, intestines, uterus, ovaries and prostate.

Ohliger's research involves new imaging methods for the abdomen and pelvis, with a focus on molecular imaging of liver tumors, liver function and liver injury. His research projects include using hyperpolarized carbon-13 MRI to capture images of liver tumors and to help diagnose fatty liver disease. He also works on developing novel imaging methods for diagnosing bacterial infections. Ohliger directs radiology research operations at Zuckerberg San Francisco General Hospital and Trauma Center.

Ohliger earned his medical degree at Harvard Medical School. He completed a medical internship at Brigham and Women's Hospital in Boston, followed by a residency in diagnostic radiology and a fellowship in abdominal imaging at UCSF. He has a doctorate in medical physics from the Harvard-Massachusetts Institute of Technology joint Division of Health Sciences and Technology.

Education & training

Board certification

  • Diagnostic Radiology, American Board of Radiology

Fellowship

  • Abdominal Imaging, UCSF Graduate Medical Education

Residency

  • Diagnostic Radiology, UCSF Medical Center - OMAG

Internship

  • Internal Medicine, Brigham and Womens Hospital GME

Degree

  • MD, Harvard Medical School

My expertise

Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.

For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.